Roche and Philadelphia gene therapy pioneer Spark Therapeutics have amended their proposed $4.3 billion merger deal to extend the deadline for completing the transaction from the end of this year to the end of April 2020.
In documents filed with the Securities and Exchange Commission, Spark said the companies agreed to the new date in order to provide them with additional time to satisfy the regulatory conditions, with respect to antitrust laws, "in the event that additional time is necessary."
